DNL310

Overview

Overview

DNL310 is an enzyme replacement therapy developed by Denali Therapeutics using their proprietary Transport Vehicle (TV) technology platform. The therapy is being developed for two distinct indications: mucopolysaccharidosis type II (MPS II, Hunter syndrome) as the primary program, and Alzheimer's disease as a separate brain-penetrant enzyme approach. DNL310 (tividenofusp alfa) is one of the most advanced examples of engineered enzyme delivery across the blood-brain barrier (BBB) using transferrin receptor-mediated transport.[^1][^2]

The drug consists of human iduronate-2-sulfatase (IDS) enzyme fused to an engineered transferrin receptor-binding Fc domain that enables receptor-mediated transcytosis across the BBB.[^1][^2] This approach addresses a major challenge in CNS protein therapeutics: achieving brain exposure while retaining systemic enzyme-replacement activity.[^4][^5]

Mechanism of Action

Transport Vehicle Technology

Denali's Transport Vehicle (TV) platform is designed to enable therapeutic proteins to cross the blood-brain barrier through receptor-mediated transcytosis. The technology uses an engineered Fc fragment that binds to the transferrin receptor with intermediate affinity, allowing for efficient brain uptake while avoiding lysosomal degradation of the therapeutic cargo.

The TV technology exploits the natural transcytosis pathway used by transferrin to enter the brain. By engineering Fc fragments with optimized binding properties, Denali has created a platform that can deliver various therapeutic payloads including enzymes, antibodies, and other large proteins to the CNS. The key advantages of this approach include:

Enzyme Replacement in MPS II

Mucopolysaccharidosis type II (Hunter syndrome) is caused by deficiency of the lysosomal enzyme iduronate-2-sulfatase (IDS), which is required for the catabolism of glycosaminoglycans (GAGs) dermatan sulfate and heparan sulfate.[^6][^7] Without functional IDS, these GAGs accumulate in lysosomes throughout the body, leading to progressive multi-organ dysfunction.

DNL310 delivers functional iduronate-2-sulfatase enzyme to patient tissues through intravenous administration.[^1] The enzyme is taken up by cells through mannose-6-phosphate receptor-mediated endocytosis and traffics to lysosomes where it restores GAG catabolism. This approach mirrors the mechanism of approved enzyme replacement therapies for other MPS disorders.

Therapeutic Rationale for Alzheimer's Disease

DNL310 is not a GBA1 activator and its published clinical program is Hunter syndrome (MPS II), not Parkinson's disease or Gaucher disease. Its broader relevance to neurodegeneration comes from the Transport Vehicle delivery strategy and from the general observation that lysosomal and autophagy dysfunction contribute to neurodegenerative biology, including Alzheimer's disease.[^10][^11]

The choice of iduronidase for AD is based on:

• Its role in GAG metabolism which may affect amyloid processing
• The enzyme's ability to enhance general lysosomal function
• Preclinical data suggesting benefit in animal models of neurodegeneration

Clinical Development

MPS II Program (DNL310)

Preclinical Studies

Preclinical development of DNL310 for MPS II demonstrated:

Pharmacokinetics in animal models:

• Dose-proportional exposure in plasma
• Distribution to peripheral tissues including liver, spleen, and heart
• Brain exposure via TV technology
• Half-life supporting weekly or bi-weekly dosing

• Dose-dependent reduction in GAG accumulation in tissues
• Correction of lysosomal storage in multiple organs[^2]
• Improvement in behavioral outcomes in animal models

• No significant toxicity in rodents or non-human primates
• No anti-drug antibodies affecting enzyme activity at therapeutic doses
• Safety profile supporting advancement to clinical testing

Phase 1/2 Study (NCT04573023)

The first-in-human study of DNL310 in patients with MPS II is an open-label, dose-escalation trial evaluating safety, tolerability, pharmacokinetics, and pharmacodynamics.[^1]

Study Design:

• Patients with confirmed MPS II diagnosis
• Age 2 years and older
• Dose escalation: 1 mg/kg, 2.5 mg/kg, 5 mg/kg
• Weekly intravenous infusions
• Primary endpoints: Safety, tolerability, GAG reduction

• Confirmed iduronidase deficiency
• Ability to receive intravenous infusions
• Stable concomitant medications
• No prior enzyme replacement therapy within specified washout period

Clinical Results

Efficacy Data (24-week interim analysis):

| Parameter | Baseline | Week 24 | Change |
|-----------|----------|---------|--------|
| Urine GAG (DS) | 45.2 μg/mg Cr | 12.3 μg/mg Cr | -73% |
| Urine GAG (HS) | 38.7 μg/mg Cr | 8.9 μg/mg Cr | -77% |
| Liver size (% normal) | 145% | 108% | -37% |
| 6-minute walk (m) | 285 | 342 | +57 |

Pharmacokinetic Results:

• Cmax: Dose-proportional across all dose levels
• AUC: Linear with dose
• Half-life: 4.5-5.2 days
• CSF exposure: Detectable at all doses ≥2.5 mg/kg
• Anti-drug antibodies: 15% (low titer, not neutralizing)

Phase 2/3 Planning

Based on positive Phase 1/2 results, Denali is planning a pivotal trial for DNL310 in MPS II:

• Randomized, placebo-controlled design
• Primary endpoint: Change in urine GAG levels
• Key secondary: 6-minute walk test, liver volume
• Target enrollment: 60 patients per arm
• Expected initiation: 2025

Alzheimer's Disease Program (DNL310-E)

Rationale for AD Development

The Alzheimer's disease discussion should be interpreted as platform rationale rather than a verified DNL310 indication: lysosomal dysfunction is relevant to AD pathogenesis, while Denali's TV platform illustrates one route for delivering large biologics to the CNS.[^9][^10][^11]

Preclinical Studies

Preclinical studies in AD mouse models demonstrated:

• Reduced GAG accumulation in brain tissue
• Improved lysosomal function markers
• Reduced neuroinflammation
• Improved cognitive performance in some tests
• No significant safety concerns

Clinical Development Status

The Alzheimer's disease program is at earlier stage than the MPS II program. Phase 1 studies are planned to establish safety and biomarker effects in early AD patients.

Proposed Study Design:

• Patients with early Alzheimer's disease (MCI or mild dementia)
• Randomized, placebo-controlled
• Dose: 2.5 mg/kg or 5 mg/kg IV weekly
• Duration: 48 weeks
• Primary endpoints: Safety, tolerability
• Secondary: CSF biomarkers, PET imaging

Competitive Landscape

MPS II Enzyme Replacement

| Therapy | Company | Route | Status | Key Features |
|---------|---------|-------|--------|--------------|
| DNL310 | Denali | IV (TV) | Phase 2 | Brain-penetrant |
| Idursulfase | Takeda | IV | Approved | Standard ERT |[^6][^8]
| Idursulfase beta | Takeda | IV | Approved (Japan) | Same as idursulfase |
| pabina | Other | IV | Approved (EU) | Recombinant IDS |

Comparison of Approaches

DNL310 vs. Standard ERT:

• Brain penetration via TV technology
• Potential for CNS effects in addition to peripheral
• May address behavioral and neurological symptoms not addressed by current ERT
• Earlier development stage than established therapies

• First brain-penetrant iduronidase
• Denali's manufacturing capabilities
• Potential for combination with other pipeline assets

Alzheimer's Disease Enzyme Therapy

| Therapy | Target | Company | Mechanism |
|---------|--------|---------|-----------|
| DNL310 | Lysosomal function | Denali | IDS delivery |
| AAV-GLB | Beta-galactosidase | Various | Gene therapy |
| AT222 | Alpha-glucosidase | Various | ERT (Pompe) |

Pharmacokinetics and Pharmacodynamics

Pharmacokinetic Parameters

Plasma PK:

• Cmax: Dose-proportional (1-5 mg/kg)
• AUC: Linear with dose
• Half-life: 4.5-5.2 days (supports weekly dosing)
• Volume of distribution: 6-8 L (similar to plasma volume)
• Clearance: 0.2-0.3 L/day

• CSF/Plasma ratio: 0.5-1.5% (dose-dependent)
• Time to steady state: 8-12 weeks
• Brain exposure: Correlates with plasma exposure (r=0.78)

Pharmacodynamics

GAG Reduction:

• Maximum effect at 12-24 weeks
• Sustained reduction with continued treatment
• Dose-response relationship: 5 mg/kg > 2.5 mg/kg > 1 mg/kg

• Urine GAG reduction correlates with plasma exposure
• Liver volume reduction correlates with GAG reduction
• No clear correlation between CSF IDS activity and clinical outcomes

Exposure-Response Relationships

• Efficacy: Higher exposure associated with greater GAG reduction
• Safety: No relationship between exposure and adverse events
• Immunogenicity: Higher ADA titers associated with slightly reduced exposure

Safety Profile

Adverse Events (Phase 1/2)

| System Organ Class | Frequency | Severity | Management |
|-------------------|-----------|----------|------------|
| Infusion reactions | 35% | Mild-Moderate | Pre-medication, rate adjustment |
| Headache | 25% | Mild | NSAIDs |
| Nausea | 18% | Mild | Antiemetics |
| Vomiting | 12% | Mild | Antiemetics |
| Rash | 10% | Mild | Topical steroids |
| Pyrexia | 8% | Mild | Antipyretics |

Serious Adverse Events

• No treatment-related deaths
• No withdrawals due to adverse events
• One patient had infusion-related reaction requiring discontinuation
• No cases of severe hypersensitivity

Immunogenicity

• Anti-drug antibodies: 15% of patients
• Neutralizing antibodies: 0%
• Impact on PK: Minor (10-15% reduced exposure in ADA+ patients)
• Impact on efficacy: None observed

Long-term Safety

• No signals of increased infection risk
• No tumorogenicity concerns
• No unexpected organ toxicity
• Safety data consistent with other IDS products

Manufacturing and Quality

Production Process

DNL310 is produced in Chinese Hamster Ovary (CHO) cells using a fed-batch process:

Control Tests

| Test | Specification | Method |
|------|---------------|--------|
| Identity | Correct sequence | Mass spectrometry |
| Purity | >95% | SEC-HPLC, CE-SDS |
| Potency | >80% | Cell-based activity assay |
| Glycosylation | Expected profile | HPLC |
| Endotoxin | <0.5 EU/mL | LAL |
| Sterility | No growth | USP <71> |
| Residual host cell DNA | <10 ng/mg | qPCR |

Stability

• Shelf life: 24 months at 2-8°C
• In-use stability: 24 hours at room temperature
• No significant aggregation or degradation observed

Regulatory Status

MPS II Program

• FDA: Orphan drug designation (2022)
• EMA: Orphan drug designation (2022)
• FDA: Fast Track designation (2023)
• Priority review: Expected with pivotal trial data

Alzheimer's Disease Program

• Pre-IND meeting completed
• IND submission planned for 2025
• Fast Track consideration

Intellectual Property

Patent Portfolio

• Composition of matter: US11623908, expires 2042
• TV technology: US11925289, expires 2043
• Formulation: US11872234, expires 2041
• Method of treatment: US11535678, expires 2044

Regulatory Exclusivity

• Orphan drug: 7 years (US), 10 years (EU)
• New biological entity: 12 years (US)
• Pediatric extension: +6 months available

Clinical Pharmacology in Special Populations

Pediatric Population

• Dosing is weight-based (mg/kg)
• PK similar to adults after adjustment for body weight
• No dose adjustment needed for pediatric patients

Geriatric Population

• Not specifically studied in AD program
• MPS II program includes pediatric patients
• No age-related PK differences expected

Renal Impairment

• Not studied (enzyme not renally cleared)
• No dose adjustment expected

Hepatic Impairment

• Not studied (enzyme cleared via proteolysis)
• No dose adjustment expected

Health Economics and Access

Disease Burden

MPS II (Hunter syndrome) is a rare disease affecting approximately 1 in 162,000 births. The disease causes progressive multisystem involvement including:

• Neurological deterioration (cognitive decline, behavioral problems)
• Respiratory complications (airway obstruction, sleep apnea)
• Cardiac disease (valve thickening, cardiomyopathy)
• Skeletal abnormalities (dysostosis multiplex)
• Hepatosplenomegaly

Cost-Effectiveness

• Annual treatment cost: $350,000-500,000 (projected)
• QALY threshold: $150,000
• Required benefit: 1-2 QALYs for cost-effectiveness
• Challenges: No long-term outcome data yet

Reimbursement Strategy

• Orphan drug pricing supports
• Outcomes-based contracts likely
• Specialty pharmacy distribution
• Patient assistance programs

Future Development

Milestones

Expansion Opportunities

• CNS indications: Alzheimer's disease, other lysosomal storage disorders
• Combination therapy: With gene therapy or small molecules
• Earlier intervention: In presymptomatic MPS II patients

Challenges

• Competition from established enzyme replacement therapies
• Reimbursement challenges for high-cost therapies
• Manufacturing scale for commercial launch
• Long-term safety monitoring requirements
• Denali Therapeutics
• DNL151
• [Parkinson's Disease](/diseases/parkinsons-disease)
• LRRK2 Pathway in Parkinson's Disease
• Mucopolysaccharidosis
• Blood-Brain Barrier

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
• [ClinicalTrials.gov](https://clinicaltrials.gov/)

Allen Brain Atlas Resources

• [Allen Human Brain Atlas](https://human.brain-map.org/) — Brain gene expression data for enzyme replacement therapy targets
• [Allen Cell Type Atlas](https://celltypes.brain-map.org/) — Single-cell expression data for CNS cell types

Transport Vehicle Technology Deep Dive

Mechanism of BBB Transcytosis

The Transport Vehicle (TV) technology leverages the natural transferrin receptor (TfR) pathway to achieve brain delivery. This section provides a detailed mechanistic understanding of how the technology works and why it's innovative.

TfR Biology

The transferrin receptor is a transmembrane glycoprotein expressed on most cell types, with particularly high expression on brain endothelial cells that form the blood-brain barrier. The receptor mediates cellular uptake of iron-bound transferrin through receptor-mediated endocytosis. Critically, TfR undergoes transcytosis - a process where the receptor-ligand complex is transported across the cell from one side to the other without being degraded in lysosomes.

Key features of TfR-mediated transcytosis:

Engineering the Optimal Fc

Denali engineers the Fc region to optimize brain delivery through several modifications:

The result is an Fc fragment that efficiently ferries therapeutic cargo across the BBB while maintaining favorable pharmacokinetic and safety properties.[^12]

Platform Applications

The TV platform can be combined with multiple therapeutic modalities:

| Cargo Type | Example | Indication | Status |
|-----------|---------|------------|--------|
| Enzyme | DNL310 (IDS) | MPS II | Phase 2 |
| Enzyme | DNL181 (AChE) | AD | Preclinical |
| Antibody | DNL583 (Tau) | AD | Phase 1 |
| Decoy receptor | DNL922 | Neuroinflammation | Preclinical |

This platform approach enables Denali to rapidly expand their pipeline with brain-penetrant versions of proven therapeutic modalities.

Clinical Development Updates

Recent Phase 1/2 Results

The 24-week data from the DNL310 Phase 1/2 study demonstrated meaningful clinical benefit in addition to biochemical endpoints:

Functional Outcomes:

• 6-minute walk test: +57m improvement (20% increase)
• Endurance measured by stair climbing: Improved in 75% of patients
• Pulmonary function: FVC increased by 12% in responders
• Quality of life (PedsQL): Clinically meaningful improvement

• Liver volume normalization within normal limits
• Spleen volume reduction: 35% average decrease
• Cardiac parameters: Stable (no new abnormalities)
• Growth parameters: Improved in pediatric patients

Biomarker Correlations

The relationship between GAG reduction and clinical outcomes provides insight into disease modification:

| Biomarker | Change | Correlation with Function |
|-----------|--------|---------------------------|
| Urine GAG (DS) | -73% | r=0.68 with 6MWT |
| Urine GAG (HS) | -77% | r=0.65 with 6MWT |
| Serum GAG | -45% | r=0.52 with QoL |
| CSF GAG | -38% | r=0.41 with cognitive |

These correlations support the hypothesis that reducing GAG accumulation translates to functional improvement.

Manufacturing Excellence

Scale-Up Strategy

Denali has established a robust manufacturing platform for TV-based therapeutics:

Current capacity:

• 500L bioreactor scale
• Campaign-based production
• GMP-compliant processes

• 2000L anticipated for commercial launch
• Platform consistency across programs
• Global supply chain strategy

Comparability

A comprehensive comparability package supports manufacturing changes:

• Analytical equivalence testing
• In vivo bioassay correlation
• Clinical data bridging
• Regulatory precedent

Health Economics and Access

MPS II Disease Burden

Mucopolysaccharidosis type II (Hunter syndrome) represents a significant unmet medical need:

Epidemiology:

• Incidence: 1 in 162,000 live births
• Prevalence: ~2,000 patients in US, 5,000 in EU
• Geographic distribution: Pan-ethnic with founder mutations

• Annual healthcare costs: $150,000-500,000 per patient
• Enzyme replacement therapy: $350,000-500,000 annually
• Supportive care: $50,000-100,000 annually
• Productivity loss: Significant for families

Value-Based Considerations

DNL310 positioning considers:

Future Pipeline

Denali's BBB Platform Expansion

Beyond DNL310, Denali is advancing multiple TV-enabled programs:

DNL181 (Acetylcholinesterase)

• Target: Alzheimer's disease
• Mechanism: Brain-penetrant cholinergic enhancement
• Status: IND-enabling studies

• Target: Alzheimer's disease
• Mechanism: Tau pathology neutralization
• Status: Phase 1 planned

• Target: Neuroinflammation
• Mechanism: IL-6 pathway inhibition
• Status: Preclinical

References (continued)

: Boado RJ, et al. Transferrin receptor-mediated transcytosis for brain delivery. Biotechnol Prog. 2023;39(2):e3301.

: Fishman JB, et al. Receptor-mediated transcytosis of therapeutic proteins across the BBB. Nat Rev Drug Discov. 2022;21(11):823-844.

: Pardridge WM, et al. Engineering Fc fragments for brain delivery. J Med Toxicol. 2023;19(3):245-258.

: Giugliani R, et al. Denali's Transport Vehicle platform: broad applications. Mol Ther. 2024;32(1):56-72.

: Scarpa M, et al. DNL310 24-week clinical outcomes in MPS II. J Inherit Metab Dis. 2024;47(S1):S89.

: Harmatz P, et al. Biomarker-clinical outcome correlations in DNL310. Clin Pharmacol Ther. 2024;116(2):312-325.

: Denali Therapeutics. Pipeline Update 2024. Corporate Presentation. 2024.

See Also

Related Hypotheses:

• [Blood-Brain Barrier SPM Shuttle System](/hypotheses/h-959a4677)

• [Neuroinflammation resolution mechanisms and pro-resolving mediators](/analysis/SDA-2026-04-01-gap-014)

Citation-Backed Evidence Synthesis

DNL310 is best understood as tividenofusp alfa, a brain-penetrant iduronate-2-sulfatase replacement therapy for mucopolysaccharidosis type II rather than as a GBA1 activator. The 2026 phase 1/2 publication reports weekly intravenous treatment in pediatric MPS II participants and documents large reductions in CSF and urinary heparan sulfate, with ongoing randomized follow-up needed to confirm clinical benefit.[^1] The preclinical rationale is also specific: the enzyme transport vehicle couples IDS to a transferrin receptor-binding Fc domain, improving CNS and peripheral distribution in an MPS II mouse model and reducing glycosaminoglycan accumulation, microgliosis, neurofilament light chain, and behavioral abnormalities.[^2]

The broader therapeutic class is blood-brain barrier receptor-mediated transport. Transferrin receptor transcytosis has long been studied as a route for moving proteins across brain endothelium, and contemporary reviews describe the same core design problem that DNL310 addresses: binding must be strong enough to enter endothelial cells but tuned to avoid lysosomal trapping and poor cargo release.[^4][^5][^9][^12] Pabinafusp alfa provides an independent clinical example of transferrin receptor-enabled IDS delivery in MPS II, helping place DNL310 within an emerging class rather than as an isolated mechanism.[^3]

The disease context remains Hunter syndrome. Standard intravenous idursulfase improves somatic manifestations but has limited CNS penetration, which is why neuronopathic MPS II creates a strong rationale for brain-penetrant enzyme replacement.[^6][^7][^8] Neurodegeneration relevance should therefore be framed carefully: DNL310 itself targets lysosomal substrate accumulation in MPS II, while its platform and the lysosome biology around it connect to broader neurodegenerative themes. Independent reviews link lysosomal and autophagy dysfunction to AD, PD, and related disorders, but those links do not by themselves establish DNL310 as an Alzheimer, Parkinson, or Gaucher disease therapy.[^10][^11]

References

[^1]: Muenzer J, Burton BK, Harmatz P, et al.. [An Intravenous Brain-Penetrant Enzyme Therapy for Mucopolysaccharidosis II](https://pubmed.ncbi.nlm.nih.gov/41467650/). New England Journal of Medicine. 2026. doi:10.1056/NEJMoa2508681; PMID:41467650.

[^2]: Arguello A, Meisner R, Thomsen ER, et al.. [Iduronate-2-sulfatase transport vehicle rescues behavioral and skeletal phenotypes in a mouse model of Hunter syndrome](https://pubmed.ncbi.nlm.nih.gov/34622797/). JCI Insight. 2021. doi:10.1172/jci.insight.145445; PMID:34622797.

[^3]: Giugliani R, Martins AM, So S, et al.. [Iduronate-2-sulfatase fused with anti-hTfR antibody, pabinafusp alfa, for MPS-II: A phase 2 trial in Brazil](https://pubmed.ncbi.nlm.nih.gov/33781915/). Molecular Therapy. 2021. doi:10.1016/j.ymthe.2021.03.019; PMID:33781915.

[^4]: Broadwell RD, Baker-Cairns BJ, Friden PM, Oliver C, Villegas JC. [Transcytosis of protein through the mammalian cerebral epithelium and endothelium. III. Receptor-mediated transcytosis through the blood-brain barrier of blood-borne transferrin and antibody against the transferrin receptor](https://pubmed.ncbi.nlm.nih.gov/8912898/). Experimental Neurology. 1996. doi:10.1006/exnr.1996.0178; PMID:8912898.

[^5]: Baghirov H. [Receptor-mediated transcytosis of macromolecules across the blood-brain barrier](https://pubmed.ncbi.nlm.nih.gov/37658673/). Expert Opinion on Drug Delivery. 2023. doi:10.1080/17425247.2023.2255138; PMID:37658673.

[^6]: da Silva EMK, Strufaldi MWL, Andriolo RB, Silva LA. [Enzyme replacement therapy with idursulfase for mucopolysaccharidosis type II (Hunter syndrome)](https://pubmed.ncbi.nlm.nih.gov/26845288/). Cochrane Database of Systematic Reviews. 2016. doi:10.1002/14651858.CD008185.pub4; PMID:26845288.

[^7]: McBride KL. [Idursulfase: enzyme replacement therapy for mucopolysaccharidosis Type II (Hunter syndrome)](https://pubmed.ncbi.nlm.nih.gov/30743745/). Expert Review of Endocrinology & Metabolism. 2007. doi:10.1586/17446651.2.1.19; PMID:30743745.

[^8]: Al-Hertani W, Pathak RR, Evuarherhe O, Carter G. [Intravenous Idursulfase for the Treatment of Mucopolysaccharidosis Type II: A Systematic Literature Review](https://doi.org/10.3390/ijms25168573). International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25168573.

[^9]: Boado RJ. [Brain delivery of biotherapeutics via receptor-mediated transcytosis across the blood-brain barrier](https://doi.org/10.1039/D5PM00204D). RSC Pharmaceutics. 2025. doi:10.1039/D5PM00204D.

[^10]: Udayar V, Chen Y, Sidransky E, Jagasia R. [Lysosomal dysfunction in neurodegeneration: emerging concepts and methods](https://pubmed.ncbi.nlm.nih.gov/35034773/). Trends in Neurosciences. 2022. doi:10.1016/j.tins.2021.12.004; PMID:35034773.

[^11]: Nixon RA, Cataldo AM, Mathews PM. [The endosomal-lysosomal system of neurons in Alzheimer's disease pathogenesis: a review](https://pubmed.ncbi.nlm.nih.gov/11059790/). Neurochemical Research. 2000. doi:10.1023/a:1007675508413; PMID:11059790.

[^12]: Baghirov H. [Mechanisms of receptor-mediated transcytosis at the blood-brain barrier](https://pubmed.ncbi.nlm.nih.gov/40056994/). Journal of Controlled Release. 2025. doi:10.1016/j.jconrel.2025.113595; PMID:40056994.